Associated tags: Infection, Pharmaceutical industry, Armata, NYSE, Staphylococcus aureus, Pseudomonas aeruginosa, Conference, GMP, DEL, Therapy, MSD, Drug development, Merck
Locations: CALIFORNIA
Retrieved on:
Thursday, October 10, 2019
"Todd is a proven leader with a track record of successfully driving research and development initiatives across a broad range of therapeutic indications," said Todd R. Patrick, Chief Executive Officer of Armata.
Key Points:
- "Todd is a proven leader with a track record of successfully driving research and development initiatives across a broad range of therapeutic indications," said Todd R. Patrick, Chief Executive Officer of Armata.
- "I am excited to join Armata's Board to help maximize the potential of the company's proprietary phage screening, identification and manufacturing capabilities," said Dr. Peterson.
- "With the rise of antibiotic resistance globally, common infections are becoming more difficult to treat, and new solutions are badly needed.
- Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Retrieved on:
Thursday, September 19, 2019
Bacteria,
Microorganisms,
Microbiology,
Gram-negative bacteria,
Pseudomonadales,
Pathogenic bacteria,
Bacteriophage,
Pseudomonas aeruginosa,
Staphylococcus aureus,
Pseudomonas,
Antimicrobial resistance,
Antibiotic MARINA DEL REY, Calif., Sept. 19, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that management will be participating in the Ladenburg Thalmann 2019 Healthcare Conference, which is being held September 24 in New York.
Key Points:
- MARINA DEL REY, Calif., Sept. 19, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that management will be participating in the Ladenburg Thalmann 2019 Healthcare Conference, which is being held September 24 in New York.
- The Company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
- In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
- Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage-specific GMP manufacturing.
Retrieved on:
Wednesday, August 14, 2019
MARINA DEL REY, Calif., Aug. 14, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced second quarter results and provided a corporate and clinical update.
Key Points:
- MARINA DEL REY, Calif., Aug. 14, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced second quarter results and provided a corporate and clinical update.
- Key Second Quarter and Subsequent Period Highlights:
Successfully completed the merger of C3J Therapeutics, Inc. ("C3J") and AmpliPhi Biosciences Corporation to form Armata Pharmaceuticals.
- Provided a corporate update at the 39th Annual Canaccord Genuity Growth Conference.
- In 2020, we expect to have both programs in clinical trials under U.S. Investigational New Drug (IND) applications with the FDA.
Bacteria,
Gram-negative bacteria,
Pseudomonadales,
Microorganisms,
Organisms,
Evolutionary biology,
Bacteriophage,
Pseudomonas,
Antimicrobial resistance,
Antibiotic,
Center for Innovative Phage Applications and Therapeutics,
Phage therapy The presentation is scheduled for Thursday, August 8th at 3:25pm Eastern Time.
Key Points:
- The presentation is scheduled for Thursday, August 8th at 3:25pm Eastern Time.
- Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections using its proprietary bacteriophage-based technology.
- The Company is also developing and advancing a broad pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa, leveraging its proprietary phage-specific GMP manufacturing capabilities.
- In collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
Medical specialties,
Microorganisms,
Gram-negative bacteria,
Pseudomonadales,
Pathogenic bacteria,
Drug resistance,
Bacteria,
Bacteriophage,
Pseudomonas aeruginosa,
Pseudomonas,
Staphylococcus aureus,
Multiple drug resistance Armata's lead product candidate, AP-SA01, is a Phase 1/2-ready asset that targets Staphylococcus aureus, including multidrug-resistant strains.
Key Points:
- Armata's lead product candidate, AP-SA01, is a Phase 1/2-ready asset that targets Staphylococcus aureus, including multidrug-resistant strains.
- In addition, Armata is also developing and advancing a broad pipeline of proprietary synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa.
- Armata has also partnered with Merck to develop proprietary synthetic phage candidates designed to target an undisclosed infectious disease agent.
- Dr. Schooley is the Editor-in-Chief of Clinical Infectious Diseases journal and formerly served as Chief of Division of Infectious Diseases at UCSD.
Armata's intellectual property includes multiple patent families with issued or pending claims covering the company's bacteriophage development programs and manufacturing technology.
Key Points:
- Armata's intellectual property includes multiple patent families with issued or pending claims covering the company's bacteriophage development programs and manufacturing technology.
- With these allowances, the company's global IP portfolio consists of 56 issued patents (9 U.S. and 47 ex-U.S.) and 28 pending patents (9 U.S. and 19 ex-U.S.).
- Details of the newly allowed patents are as follows:
Covers specific mutations and mutants of phage K for treatment of Staphylococcus infections.
- Armata has also partnered with Merck to develop proprietary synthetic phage candidates designed to target an undisclosed infectious disease agent.
The paper, entitled "Successful adjunctive use ofbacteriophage therapy fortreatment ofmultidrugresistant Pseudomonas aeruginosa infection inacystic fibrosis patient," appears in the peer-reviewed journal Infection.
Key Points:
- The paper, entitled "Successful adjunctive use ofbacteriophage therapy fortreatment ofmultidrugresistant Pseudomonas aeruginosa infection inacystic fibrosis patient," appears in the peer-reviewed journal Infection.
- In addition to its work with AP-PA01, Armata is engineering its Pseudomonas aeruginosa phage to create a new, synthetic phage product, AP-PA02.
- Treatment of single patients through the expanded access program has been very helpful in demonstrating the promise of phage therapy.
- In addition, Armata is also developing and advancing a broad pipeline of proprietary synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa.
